Biomarkers: Symptoms, Survivorship, and Quality of Life

Seminars in Oncology Nursing

Volumn 28, Issue 2, 2012, Pages 129-138

  Miaskowski, Christine ^a   Aouizerat, Bradley E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Depression; Fatigue; Genomics; Pain; Quality of life; Sleep disturbance; Symptoms

Indexed keywords

CYTOKINE; TUMOR MARKER;

ARTICLE; BLOOD; DEPRESSION; EARLY DIAGNOSIS; FATIGUE; GENOMICS; HUMAN; METHODOLOGY; MORTALITY; NEOPLASM; NURSING; PAIN; PATHOLOGY; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SLEEP DISORDER; UNITED STATES;

CYTOKINES; DEPRESSION; EARLY DETECTION OF CANCER; FATIGUE; GENOMICS; HUMANS; NEOPLASMS; PAIN; PROGNOSIS; QUALITY OF LIFE; SLEEP DISORDERS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84860246746     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2012.03.008     Document Type: Article

References (97)

1. Sprangers M.A., Sloan J.A., Barsevick A., et al. Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Qual Life Res 2010, 19:1395-1403.
2. Sprangers M.A., Sloan J.A., Veenhoven R., et al. The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet 2009, 12:301-311.
3. Sprangers M.A., Schwartz C.E. Reflections on changeability versus stability of health-related quality of life: distinguishing between its environmental and genetic components. Health Qual Life Outcomes 2008, 6:89.
4. Schmidt B.L., Hamamoto D.T., Simone D.A., et al. Mechanism of cancer pain. Mol Interv 2010, 10:164-178.
5. Oh H.S., Seo W.S. Systematic review and meta-analysis of the correlates of cancer-related fatigue. Worldviews Evid Based Nurs 2011, 8:191-201.
6. Barsevick A., Frost M., Zwinderman A., et al. I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 2010, 19:1419-1427.
7. Sehgal A., Mignot E. Genetics of sleep and sleep disorders. Cell 2011, 146:194-207.
8. Winkelmann J., Kimura M. Genetics of sleep disorders. Handb Clin Neurol 2011, 99:681-693.
9. Cirelli C. The genetic and molecular regulation of sleep: from fruit flies to humans. Nat Rev Neurosci 2009, 10:549-560.
10. Muller N., Myint A.M., Schwarz M.J. Inflammatory biomarkers and depression. Neurotox Res 2011, 19:308-318.
11. Lau J.Y., Eley T.C. The genetics of mood disorders. Annu Rev Clin Psychol 2010, 6:313-337.
12. Sprangers M.A., Bartels M., Veenhoven R., et al. Which patient will feel down, which will be happy? The need to study the genetic disposition of emotional states. Qual Life Res 2010, 19:1429-1437.
13. Miaskowski C., Aouizerat B.E., Dodd M., et al. Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. J Natl Cancer Inst Monogr 2007, 37:39-46.
14. Miaskowski C., Aouizerat B.E. Is there a biological basis for the clustering of symptoms?. Semin Oncol Nurs 2007, 23:99-105.
15. Cleeland C.S., Bennett G.J., Dantzer R., et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003, 97:2919-2925.
16. Miller A.H., Ancoli-Israel S., Bower J.E., et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008, 26:971-982.
17. Kiecolt-Glaser J.K., Gouin J.P., Hantsoo L. Close relationships, inflammation, and health. Neurosci Biobehav Rev 2010, 35:33-38.
18. Shi Q., Cleeland C.S., Klepstad P., et al. Biological pathways and genetic variables involved in pain. Qual Life Res 2010, 19:1407-1417.
19. Reyes-Gibby C.C., Wu X., Spitz M., et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 2008, 9:777-785.
20. Gilbertson-White S., Aouizerat B.E., Miaskowski C. Methodologic issues in the measurement of cytokines to elucidate the biological basis for cancer symptoms. Biol Res Nurs 2011, 13:15-24.
21. Tizard I. Sickness behavior, its mechanisms and significance. Anim Health Res Rev 2008, 9:87-99.
22. Myers J.S. Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Forum 2008, 35:802-807.
23. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21:153-160.
24. Gupta S.C., Kim J.H., Kannappan R., et al. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood) 2011, 236:658-671.
25. Starkweather A.R., Lyon D.E., Schubert C.M. Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy. Biol Res Nurs 2011, [Epub ahead of print].
26. Wang X.S., Shi Q., Williams L.A., et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 2010, 24:968-974.
27. Inagaki M., Isono M., Okuyama T., et al. Plasma interleukin-6 and fatigue in terminally ill cancer patients. J Pain Symptom Manage 2008, 35:153-161.
28. Seruga B., Zhang H., Bernstein L.J., et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008, 8:887-899.
29. Wood L.J., Nail L.M., Gilster A., et al. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 2006, 33:535-542.
30. Payne J.K. The trajectory of biomarkers in symptom management for older adults with cancer. Semin Oncol Nurs 2006, 22:31-35.
31. Wood L.J., Nail L.M., Perrin N.A., et al. The cancer chemotherapy drug etoposide (VP- 16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs 2006, 8:157-169.
32. Pusztai L., Mendoza T.R., Reuben J.M., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25:94-102.
33. Glaser R., Robles T.F., Sheridan J., et al. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry 2003, 60:1009-1014.
34. Bower J.E., Ganz P.A., Irwin M.R., et al. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav Immun 2011, 25:147-150.
35. Bower J.E., Ganz P.A., Tao M.L., et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res 2009, 15:5534-5540.
36. Meyers C.A., Seabrooke L.F., Albitar M., et al. Association of cancer-related symptoms with physiological parameters. J Pain Symptom Manage 2002, 24:359-361.
37. Rich T., Innominato P.F., Boerner J., et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Research 2005, 11:1757-1764.
38. Bower J.E., Ganz P.A., Aziz N., et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002, 64:604-611.
39. Bower J.E., Ganz P.A., Irwin M.R., et al. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?. J Clin Oncol 2011, 29:3517-3522.
40. Wacnik P.W., Eikmeier L.J., Simone D.A., et al. Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. Neuroscience 2005, 132:479-491.
41. Constantin C.E., Mair N., Sailer C.A., et al. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 2008, 28:5072-5081.
42. Wang X.S., Shi Q., Williams L.A., et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 2008, 113:2102-2109.
43. Al-shair K., Kolsum U., Dockry R., et al. Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res 2011, 12:3.
44. Clark I.A., Alleva L.M., Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther 2010, 128:519-548.
45. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
46. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
47. Jehn C.F., Kuhnhardt D., Bartholomae A., et al. Association of IL-6, hypothalamus- pituitary-adrenal axis function, and depression in patients with cancer. Integr Cancer Ther 2010, 9:270-275.
48. Thomas K.S., Motivala S., Olmstead R., et al. Sleep depth and fatigue: role of cellular inflammatory activation. Brain Behav Immun 2011, 25:53-58.
49. Clinton J.M., Davis C.J., Zielinski M.R., et al. Biochemical regulation of sleep and sleep biomarkers. J Clin Sleep Med 2011, 7:S38-S42.
50. O'Connor M.F., Irwin M.R. Links between behavioral factors and inflammation. Clin Pharm Ther 2010, 87:479-482.
51. Mullington J.M., Simpson N.S., Meier-Ewert H.K., et al. Sleep loss and inflammation. Best Pract Res Clin Endocrinol Metab 2010, 24:775-784.
52. Mullington J.M., Haack M., Toth M., et al. Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovas Dis 2009, 51:294-302.
53. Haack M., Sanchez E., Mullington J.M. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep 2007, 30:1145-1152.
54. Williams A., Scharf S.M. Obstructive sleep apnea, cardiovascular disease, and inflammation-is NF-kappaB the key?. Sleep Breath 2007, 11:69-76.
55. Elenkov I.J., Iezzoni D.G., Daly A., et al. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 2005, 12:255-269.
56. Pollmacher T., Haack M., Schuld A., et al. Low levels of circulating inflammatory cytokines-do they affect human brain functions?. Brain Behav Immun 2002, 16:525-532.
57. Mullington J.M., Hinze-Selch D., Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann N Y Acad Sci 2001, 933:201-210.
58. Buskila D., Sarzi-Puttini P., Ablin J.N. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007, 8:67-74.
59. Landmark-Hoyvik H., Reinertsen K.V., Loge J.H., et al. The genetics and epigenetics of fatigue. PM R 2010, 2:456-465.
60. Lyon D.E., McCain N.L., Pickler R.H., et al. Advancing the biobehavioral research of fatigue with genetics and genomics. J Nurs Scholarsh 2011, 43:274-281.
61. Aouizerat B.E., Miaskowski C.A., Gay C., et al. Risk factors and symptoms associated with pain in HIV-infected adults. J Assoc Nurses AIDS Care 2010, 21:125-133.
62. Miaskowski C. Understanding the genetic determinants of pain and pain management. Semin Oncol Nurs 2009, 25:S1-S7.
63. Kim H., Clark D., Dionne R.A. Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J Pain 2009, 10:663-693.
64. Fillingim R.B., Wallace M.R., Herbstman D.M., et al. Genetic contributions to pain: a review of findings in humans. Oral Dis 2008, 14:673-682.
65. Ishii T., Wakabayashi R., Kurosaki H., et al. Association of serotonin transporter gene variation with smoking, chronic obstructive pulmonary disease, and its depressive symptoms. J Human Gen 2011, 56:41-46.
66. Danese A. Genetic opportunities for psychiatric epidemiology: on life stress and depression. Epidemiol Psichiatr Soc 2008, 17:201-210.
67. Turek F.W. From circadian rhythms to clock genes in depression. Int Clin Psychopharmacol 2007, 22(suppl 2):S1-S8.
68. Ban H.J., Kim S.C., Seo J., et al. Genetic and metabolic characterization of insomnia. PLoS ONE 2011, 6:e18455.
69. McClung C.A. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007, 114:222-232.
70. Taheri S. The genetics of sleep disorders. Minerva Med 2004, 95:203-212.
71. Collado-Hidalgo A., Bower J.E., Ganz P.A., et al. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav Immun 2008, 22:1197-1200.
72. Aouizerat B.E., Dodd M., Lee K., et al. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol Res Nurs 2009, 11:27-41.
73. Miaskowski C., Dodd M., Lee K., et al. Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J Pain Symptom Manage 2010, 40:531-544.
74. Reyes-Gibby C.C., Spitz M.R., Yennurajalingam S., et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev 2009, 18:2636-2642.
75. Reyes-Gibby C.C., Shete S., Yennurajalingam S., et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage 2009, 38:894-902.
76. Reyes-Gibby C.C., El Osta B., Spitz M.R., et al. The influence of tumor necrosis factor- alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev 2008, 17:3262-3267.
77. Reyes-Gibby C.C., Spitz M., Wu X., et al. Cytokine genes and pain severity in lung cancer: Exploring the influence of TNF-{alpha}-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev 2007, 16:2745-2751.
78. Gerretsen P., Muller D.J., Tiwari A., et al. The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin Neurosci 2009, 11:363-376.
79. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005, 5:6-13.
80. Ingelman-Sundberg M., Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 2005, 360:1563-1570.
81. de Leon J., Susce M.T., Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 2006, 10:135-151.
82. Gaedigk A., Bradford L.D., Marcucci K.A., et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharm Ther 2002, 72:76-89.
83. Stamer U.M., Stuber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 2007, 20:478-484.
84. Stamer U.M., Stuber F. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. Anaesthesia 2007, 62:1294-1295.
85. Kirchheiner J., Schmidt H., Tzvetkov M., et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007, 7:257-265.
86. de Leon J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2006, 6:277-286.
87. Bartels M., Boomsma D.I. Born to be happy? The etiology of subjective well-being. Behav Genet 2009, 39:605-615.
88. Caprara G.V., Fagnani C., Alessandri G., et al. Human optimal functioning: the genetics of positive orientation towards self, life, and the future. Behav Genet 2009, 39:277-284.
89. Offit K. Personalized medicine: new genomics, old lessons. Hum Genet 2011, 130:3-14.
90. Avard D., Knoppers B.M. Genomic medicine: considerations for health professionals and the public. Genome Med 2009, 1:25.
91. Chan I.S., Ginsburg G.S. Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 2011, 12:217-244.
92. Dhruva A., Dodd M., Paul S.M., et al. Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy. Cancer Nurs 2010, 33:201-212.
93. Dunn L.B., Aouizerat B.E., Cooper B.A., et al. Trajectories of anxiety in oncology patients and family caregivers during and after radiation therapy. Eur J Oncol Nurs 2011, 16:1-9.
94. Dunn L.B., Cooper B.A., Neuhaus J., et al. Identification of distinct depressive symptom trajectories in women following surgery for breast cancer. Health Psychol 2011, 30:683-692.
95. Carle A.C., Cella D., Cai L., et al. Advancing PROMIS's methodology: results of the Third Patient-Reported Outcomes Measurement Information System (PROMIS®) Psychometric Summit. Expert Rev Pharmacoecon Outcomes Res 2011, 11:677-684.
96. Robinson D.W., Eisenberg D.F., Cella D., et al. The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol 2008, 6:283-290.
97. Seidman A.D., Portenoy R., Yao T.J., et al. Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 1995, 87:1316-1322.